<DOC>
	<DOCNO>NCT02175758</DOCNO>
	<brief_summary>This study two part follow : The PK Lead-in Phase study evaluate steady state pharmacokinetics ( PK ) confirm dose sofosbuvir ( SOF ) hepatitis C virus ( HCV ) -infected pediatric participant . The PK Lead-in Phase also evaluate safety tolerability 7 day dose SOF+ribavirin ( RBV ) HCV-infected pediatric participant . The Treatment Phase initiate age cohort confirmation age-appropriate SOF dosage level . Participants PK Lead-in Phase immediately rollover Treatment Phase interruption study drug administration . The Treatment Phase evaluate antiviral efficacy , safety , tolerability SOF+RBV 12 24 week pediatric participant genotype 2 3 HCV infection , respectively .</brief_summary>
	<brief_title>Safety Efficacy Sofosbuvir + Ribavirin Adolescents Children With Genotype 2 3 Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Consent parent legal guardian require Chronic HCV infection genotype 2 3 Screening laboratory value within define threshold PK Leadin : individual must treatment naive Key History clinically significant illness medical disorder may interfere subject treatment , assessment compliance protocol Coinfection HIV , acute hepatitis A virus , hepatitis B virus Clinical hepatic decompensation ( ie , ascites , encephalopathy variceal hemorrhage ) Pregnant nursing female Known hypersensitivity study medication Use prohibit concomitant medication within 28 day Day 1 visit Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>